Everything below concerns quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Weight regain is common upon discontinuation of weight loss medications, and long-term therapy may sometimes be required for sustained weight loss. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year. People return to their previous weight within a year and a half after stopping anti-obesity medications. Media related to Anti-obesity drugs at Wikimedia Commons Prescription Medications to Treat Overweight & Obesity US National Institute of Diabetes and Digestive and Kidney Diseases
Among the actinides, thorium and uranium are the easiest to isolate. Thorium is extracted mostly from monazite: thorium pyrophosphate (ThP2O7) is reacted with nitric acid, and the produced thorium nitrate treated with tributyl phosphate. Rare-earth impurities are separated by increasing the pH in sulfate solution. In another extraction method, monazite is decomposed with a 45% aqueous solution of sodium hydroxide at 140 °C. Mixed metal hydroxides are extracted first, filtered at 80 °C, washed with water and dissolved with concentrated hydrochloric acid. Next, the acidic solution is neutralized with hydroxides to pH = 5.8 that results in precipitation of thorium hydroxide (Th(OH)4) contaminated with ~3% of rare-earth hydroxides; the rest of rare-earth hydroxides remains in solution. Thorium hydroxide is dissolved in an inorganic acid and then purified from the rare earth elements. An efficient method is the dissolution of thorium hydroxide in nitric acid, because the resulting solution can be purified by extraction with organic solvents:
== Side effects == Frequently reported side effects include: nausea, heartburn, weight gain, and bloating. The medication is also a major cause of medication-induced hypoglycemia. The risk is greater than with other sulfonylureas.
On 7 August 2013, President Saakashvili said in an interview with Rustavi 2 TV that "the worst time for Georgia to engage in [military actions] was summer of 2008 and Russians knew it very well." Saakashvili said he offered Vladimir Putin in February 2008 to give up Georgia's NATO aspirations in exchange for Russia's help in restoring Georgia's control over the breakaway territories and that Georgia would endorse Russia's regional interests, but Putin refused by saying, "We do not exchange your territories for your geopolitical orientation." Saakashvili said that when he complained to Putin about escalation in the South Ossetian conflict zone, Putin threatened that the situation would even further deteriorate. Saakashvili said that Condoleezza Rice was assuring him in 2008 that there would be no war while Frank-Walter Steinmeier, German foreign minister, was the first to warn him about impending Russian attack. Saakashvili commented about the end of war in August 2008, "Eventually it was diplomacy and the U.S. sixth fleet that stopped Russia;" In March 2014, former president of Georgia, Mikheil Saakashvili wrote in The Washington Post, "Almost every Western politician to whom my government raised concerns in [July 2008] said that Russia would not attack and urged us to keep calm and not react to Russian moves." Saakashvili published an article in The Guardian where he wrote that "if the west had reacted properly to Georgia, Ukraine would never have happened." The Tagliavini Commission and actions of the EU emboldened Putin to act against Ukraine.
It is an epiphytic and occasionally a lithophytic plant, forming spectacular root bundles. Its cylindric pseudobulbs can grow to a length of 2.5 m. It can grow to gigantic clusters weighing from several hundred kilograms to more than one tonne. One collected in 1893 by Frederick K. Sander & Co. near Penang Island in Malaysia weighed 1 t (0.98 long tons; 1.1 short tons). Half was sent to the Columbian Exhibition in Chicago and the other half to the Singapore Botanic Garden. By 1902, the Singapore specimen had grown to be 14.4 m (47 ft) girth by 3 m (9.8 ft) high, and bore simultaneously 2,090 12.5 cm (4.9 in) wide gold and mahogany-coloured flowers plus 1110 unopened buds. Much more recently, in A.D. 2000, biologists Tim Laman and Phil Atkinson found one in Borneo 7.7 m (25 ft) wide and bearing between 2500 and 5000 flowers. The plant completely encircled the host tree 46 m (151 ft) above the ground. The oldest known individual orchid plant is also a G. speciosum. Planted in the Singapore Botanic Garden in 1861 by Garden Director Lawrence Niven and his staff, it was 154 years old in 2015. The plant is also 5 m (16 ft) in width. Each raceme can grow to a height of 3 m, bearing up to 80 flowers, each 10 cm wide. The flowers are yellow with maroon or dark red spots. These flowers are unusual, since the lowest flowers have no lip and these flowers function as osmophores for the entire inflorescence and continue to emit chemical scent to attract pollinators as flowers open in succession. It blooms only once every two to four years.
Sources: en.wikipedia.org
== Reaction mechanism == BHBDH is found in the mitochondria and catalyzes the oxidation of 3-hydroxybutyyrate to acetoacetate and it uses NAD as a coenzyme. The reaction is shown below and as denoted by the formula it is reversible. As outlined in the reaction formula, this enzyme catalyzes the reaction of (R)-3-hydroxybutanoate and NAD+ into acetoacetate into NADH and a free H+. (R)-3-hydroxybutanoate + NAD+
Protein misfolding cyclic amplification (PMCA) is an amplification technique (conceptually like polymerase chain reaction (PCR) but not involving nucleotides) to multiply misfolded prions originally developed by Soto and colleagues. It is a test for spongiform encephalopathies like chronic wasting disease (CWD) or bovine spongiform encephalopathy (BSE).
A balanced salt solution (BSS) is a solution made to a physiological pH and isotonic salt concentration. Solutions most commonly include sodium, potassium, calcium, magnesium, and chloride. Balanced salt solutions are used for washing tissues and cells and are usually combined with other agents to treat the tissues and cells. They provide the cells with water and inorganic ions, while maintaining a physiological pH and osmotic pressure. Sometimes glucose is added as an energy source and phenol red is used as a pH indicator. In medicine, balanced salt solutions can be used as an irrigation solution such as during intraocular surgery and to replace intraocular fluids.
=== Views on golf === In July 2007, Player made statements at the Open Championship golf tournament about the use of performance-enhancing drugs in golf. He alleged that at least ten players were "taking something", citing human growth hormone, steroids and creatine as possible substances. Both the PGA Tour and European Tour were in the process of introducing random testing programmes at the time. In June 2016, in an interview with bunkered.co.uk, Player branded as "laughable" a report released by the R&A and USGA governing bodies which said that driving distance in golf was only increasing minimally. He warned of a "tsunami coming" due to the governing bodies' failure to address issues surrounding new golf technology. After the 2017 Alfred Dunhill Links Championship, Player reiterated these comments, taking to messaging service Twitter to say he was sad to see the Old Course at St Andrews "brought to her knees" after Ross Fisher broke the course record on a day of very low scoring during the final round.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.